The canine arthritis treatment market is estimated at USD 2.7 billion in 2026, is projected to reach USD 4.1 billion by 2036 and is forecast to register a 4.2% CAGR between 2026 and 2036. In 2026, NSAIDs hold 47.3% within the treatment type segment and oral formulations represent 55.6% of the route of administration category.